Stammdaten
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Unternehmen & Branche
| Name | Azitra, Inc. |
|---|---|
| Ticker | AZTR |
| CIK | 0001701478 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,7 Mio. USD |
| Beta | -2,18 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -10,955,370 | -2.25 | 5,025,386 | 3,801,230 |
| 2025-09-30 | 10-Q | 0 | -2,764,528 | -0.67 | 4,300,279 | 2,279,176 |
| 2025-06-30 | 10-Q | 0 | -2,888,993 | -0.18 | 3,956,022 | 2,228,971 |
| 2025-03-31 | 10-Q | -3,068,345 | -0.23 | 5,907,891 | 4,407,625 | |
| 2024-12-31 | 10-K | 7,500 | -8,967,492 | -15.70 | 7,358,802 | 5,698,298 |
| 2024-09-30 | 10-Q | 0 | -1,009,491 | -1.14 | 9,777,499 | 8,058,253 |
| 2024-06-30 | 10-Q | 7,500 | -2,631,993 | -2.74 | 3,882,554 | 1,726,166 |
| 2024-03-31 | 10-Q | 0 | -2,932,875 | -4.32 | 6,067,993 | 4,324,216 |
| 2023-12-31 | 10-K | 686,000 | -11,283,781 | -54.98 | 5,115,486 | 2,913,146 |
| 2023-09-30 | 10-Q | 310,700 | -1,943,289 | -4.82 | 7,490,244 | 5,332,086 |
| 2023-06-30 | 10-Q | 172,000 | -4,429,528 | -70.83 | 9,829,557 | 7,236,302 |
| 2023-03-31 | 10-Q | 113,300 | -2,457,180 | -3.00 | -38,678,696 | |
| 2022-12-31 | 10-K | 284,000 | -10,680,366 | -12.74 | 7,167,443 | -36,260,310 |
| 2022-09-30 | 10-Q | 48,500 | -2,417,620 | -2.95 | -32,243,061 | |
| 2022-06-30 | 10-Q | 85,000 | -1,890,153 | -2.45 | -29,869,770 | |
| 2022-03-31 | 10-Q | -2,326,017 | -28,033,443 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.